Introduction: The objective of this article is to evaluate the antiproteinuric effect of angiotensin receptor blockers (ARBs) in normotensive patients with proteinuria. Materials and methods: We reviewed randomized controlled trials assessing ARBs treatment in patients with normotension and proteinuria. Data concerning the study design, patient characteristics, and outcomes were extracted. Ratio of means was calculated by using the generalized inverse variance method. Results: Eight trials involving 866 patients were included in this study. Compared with a control group, ARBs group was associated with a significant reduction in urinary protein excretion (ratio of means 0.53, 95% CI 0.44-0.64). Subgroup analysis shows that ARBs therapy resulted in a significant decrease in urinary protein excretion in diabetic patients with microalbuminuria or nondiabetic nephropathy with overt proteinuria (ratio of means 0.57, 95% CI 0.47-0.69 and 0.46, 95% CI 0.26-0.83, respectively), in a Western population or an Asian population (ratio of means 0.61, 95% CI 0.54-0.69 and 0.49, 95% CI 0.37-0.64, respectively), and in patients followed up for one to three months or three to 12 months (ratio of means 0.62, 95% CI 0.54-0.70 and 0.49, 95% CI 0.38-0.63, respectively).
Introduction
Proteinuria is a strong marker of kidney damage and is closely associated with an increased risk of renal disease progression. [1] [2] [3] [4] It is also an independent risk factor for cardiovascular morbidity and mortality in diabetic or nondiabetic patients. [1] [2] [3] Several studies have shown that lowering proteinuria would retard renal disease progression [5] [6] [7] [8] and improve cardiovascular outcomes [9] [10] [11] regardless of underlying causes.
It has been considered that angiotensin II plays an important role in renal injury and renal disease progression, which promotes proliferation of renal mesangial, endothelial and tubular cells. Several large randomized controlled trials (RCTs) 5, 6 have demonstrated that angiotensin receptor blockers (ARBs) have beneficial effects on the progression of proteinuria in hypertensive patients and confirm a special renoprotective effect that appears to be independent of blood pressure reduction. Although previous meta-analyses [12] [13] [14] that evaluated the efficacy of ARBs on the development of proteinuria found a benefit of ARBs overall, little attention was paid to the antiproteinuria effect of ARBs in normotensive patients with proteinuria. Therefore, we performed this meta-analysis to investigate the effect of ARBs on the progression of proteinuria in normotensive patients with proteinuria.
Materials and methods

Search strategy
Electronic databases including PubMed and Cochrane central register of controlled trials from inception to September 2012 were searched by using the Mesh or text keywords "albuminuria," "proteinuria," "angiotensin receptor blocker," "losartan," "valsartan," "olmesartan," "telmisartan," "irbesartan," "candesartan," "normotension," "normotensive," "nonhypertension" and "normal blood pressure." Reference lists of identified studies were scrutinized to reveal additional sources. We restricted the search to human studies and clinical trials published in English.
Criteria for study selection
Studies were considered for inclusion if they met the following criteria: (1) type of study design was RCT that compared ARBs with placebo, no treatment or other antihypertensive agents (excluding angiotensin-converting enzyme inhibitors (ACEIs)) on the effect of urinary protein excretion; (2) all the participants were diabetic or nondiabetic patients with normotension and proteinuria; (3) all the trials reported the changes in urinary protein excretion from baseline irrespective of the measurement methods of it; (4) study duration ≥ four weeks. We excluded trials involving patients under 18 years of age or with renal transplantation.
Data extraction and assessment of study quality
Data were extracted independently by two investigators. Discrepancies were resolved by consensus or a third author adjudication. The following data were abstracted from each study: details of participant characteristics (age, gender, race and primary renal diseases), types and dosages of ARBs and control interventions, durations of treatment, baseline and follow-up data on urinary protein excretion rates, serum creatinine level and blood pressure, and severe drug-related adverse effects. If studies comprise two or more ARBs groups divided by different ARBs dosages, data were abstracted from the ARBs group with the lowest dosage. In crossover trials, data from period one were selected for analysis. Methodological quality of included RCTs was assessed by several domains: randomization, generation of random sequence, allocation concealment, blinding, intention to treat analysis and completeness of follow-up.
Statistical analysis
We referred to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. 15 The same problems as in the meta-analysis by Kunz and colleagues 14 also exist in our study. The ratio of the average treatment effect in the intervention group relative to the control group, which was termed as the "ratio of means," was used as effect size. 14, 16 The log-transformed ratios across the trials were aggregated by using the generalized inverse variance method. 16 Then the pooled log-transformed treatment effect was reverse transformed to the original scale to obtain the final overall estimate of the relative treatment effect. Heterogeneity across trials was assessed via a standard Chi square test with significance being set at p < 0.10 and also assessed by means of a I 2 statistic with significance being set at I 2 > 50%. Statistical analysis was performed using Review Manager 5.0 (The Cochrane Collaboration, Oxford, England).
Results
Study selection
A total of eight RCTs 17-24 with 866 patients were identified for inclusion from 232 potentially relevant publications ( Figure 1 ). Table 1 summarizes the baseline characteristics and study quality of the included trials. [17] [18] [19] [20] [21] [22] [23] [24] The confounding factors that affected urinary protein excretion were well balanced in each arm. Among these trials, six studies [17] [18] [19] [22] [23] [24] defined normotension as blood pressure less than 140/90 mmHg, one trial 20 defined normotension as blood pressure less than 150/90 mmHg, and one other trial 21 mentioned baseline mean arterial blood pressure but did not report the definition of normotension. Five trials 19,21-24 mentioned exclusion of patients previously treated with antihypertensive agents, while three trials 17,18,20 did not. Five trials 17, 19, 20, 22, 23 recruited 791 type 2 diabetic patients with microalbuminuria (91.3%, 791/866), while three trials 18, 21, 24 enrolled 75 nondiabetic nephropathy patients with overt proteinuria (8.7%, 75/866). Five studies [17] [18] [19] 21, 24 recruited Asian patients (three trials in Japan, one trial in Pakistan, one trial in Turkey), and three other trials 20, 22, 23 enrolled European patients (one trial in the United Kingdom, one trial in the Netherlands, one trial in Italy).
Study characteristics and quality
Antiproteinuric effects of ARBs
Overall, ARBs therapy was associated with a significant reduction in urinary protein excretion (ratio of means 0.53, 95% confidence interval (CI) 0.44-0.64).
According to the different primary diseases, ARBs treatment resulted in a significant reduction in urinary protein excretion in patients with early diabetic nephropathy (ratio of means 0.57, 95% CI 0.47-0.69) or nondiabetic nephropathic patients (ratio of means 0.46, 95% CI 0.26-0.83) ( Figure 2 ).
According to different stages of proteinuria, ARBs treatment was associated with a significant reduction in urinary protein excretion in patients with microalbuminuria (ratio of means 0.57, 95% CI 0.47-0.69) or overt proteinuria (ratio of means 0.46, 95% CI 0.26-0.83).
According to the different follow-up periods, ARBs therapy achieved lower levels of urinary protein excretion in patients followed up for one to three months (ratio of means 0.62, 95% CI 0.54-0.70) or three to 12 months (ratio of means 0.49, 95% CI 0.38-0.63) ( Figure 3 ).
ARB therapy was associated with a significant reduction in urinary protein excretion in the Western population (ratio of means 0.61, 95% CI 0.54-0.69) and Asian population (ratio of means 0.49, 95% CI 0.37-0.64). Table 2 shows the differences in the changes of systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine and creatinine clearance between the two groups. ARBs treatment was associated with significant decreases in SBP (weighted mean difference (WMD) -2.19 mmHg, 95% confidence limits (CL) -3.88, -0.49; p=0.01) and DBP (WMD -2.62 mmHg, 95% CL -4.06, -1.19; p=0.0004). There were no significant differences in the changes of serum creatinine and creatinine clearance between the two groups.
Changes in blood pressure, serum creatinine and creatinine clearance
Side effects
Seven trials briefly described adverse events. No serious ARBs-related adverse events were reported. The most common complaints were mild dizziness.
Discussion
This meta-analysis suggests that ARBs therapy may have beneficial effects on the progression of urinary protein excretion in patients with normotension and proteinuria, irrespective of pretreatment urinary protein levels. ARBs may have not only short-term but also long-term antiproteinuria effects in normotensive patients with proteinuria. In addition, ARBs treatment is relatively safe in such patients.
This meta-analysis has shown that ARBs therapy resulted in a significant decrease in urinary protein excretion in nondiabetic patients. Moreover, the Ramipril Efficacy In Nephropathy (REIN) study 7, 8, 25 has stated that ACEI therapy was associated with a slower decline in glomerular filtration rate and delayed progression to endstage renal disease (ESRD) in nondiabetic nephropathy patients with proteinuria. Several studies 26, 27 have demonstrated that ARBs therapy inhibits the progression of proteinuria to an extent comparable to ACEIs. Since proteinuria has been shown to be an independent risk factor for kidney outcomes, the antiproteinuric effects of ARBs may retard the progression of renal disease in nonhypertensive patients with nondiabetic nephropathy. However, due to small sample size and short-term followup periods in nondiabetic nephropathic patients, large sample size and long-term RCTs are still warranted to investigate this issue.
It has been established that microalbuminuria is not only an early marker of kidney damage but also associated with increased risks of cardiovascular disease and chronic kidney disease, resulting in poor outcomes in diabetic patients. [28] [29] [30] In the Reduction of Endpoints in Non-Insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) 6 and the Irbesartan Diabetic Nephropathy Trial (IDNT) 5 trials, ARBs therapy resulted in not only a reduction in urinary protein excretion, but also a decrease in the risks of cardiovascular and renal endpoints in hypertensive patients with type 2 diabetes mellitus (T2DM). 11, 31 In the present study, we found that ARBs treatment was linked with the reduction of urinary protein excretion in normotensive patients with T2DM. Therefore, it is reasonable to speculate that ARBs treatment may have beneficial effects on cardiovascular and renal events in normotensive patients with diabetic nephropathy. However, there is still no convincing evidence in terms of the association between reduced urinary protein excretion and decreased risks in cardiovascular and renal events in normotensive patients with diabetic nephropathy. 3 The Zandbergen et al. trial 20 has reported that 50 mg of losartan resulted in a 25% relative reduction, and 100 mg losartan achieved a 34% relative reduction in the albumin excretion rate in nonhypertensive patients with microalbuminuria, which means that ARBs have a dose-dependent effect on lowering albuminuria. The IRbesartan MicroAlbuminuria in Type 2 Diabetic Subjects (IRMA 2) trial 32 has demonstrated that 300 mg of irbesartan was superior to 150 mg in reducing microalbuminuria in hypertensive patients with T2DM. Similar results 33, 34 in hypertensive diabetic patients were also reported. The dose-dependent effect of ARBs on reducing the albumin excretion rate may exist not only in hypertensive diabetic patients but also normotensive diabetic patients. Viberti and Wheeldon 22 have shown that valsartan therapy has a significantly greater percentage of patients returning to normoalbuminuria status than amlodipine in T2DM patients with microalbuminuria. In a recent meta-analysis, 13 the effect of ARBs on regression to normoalbuminuria also appears to be dose dependent in T2DM patients with microalbuminuria. In addition, Zandbergen et al. 20 has shown that the antiproteinuric effect was reversible after discontinuation of losartan, the albumin excretion rate was 51.9 ± 36.8 μg/min at the end of therapy and 78.6 ± 64.8 μg/min after five weeks of washout in the losartan group, respectively. In hypertensive T2DM patients with microalbuminuria, an RCT 34 has shown that albuminuria increases soon after the withdrawal of these drugs even after two or more years of treatment, but it is unclear whether this reversible antiproteinuric effect of ARBs would influence cardiorenal events.
In the Microalbuminuria Reduction with Valsartan (MARVAL) trial, 22 for the same level of attained blood pressure, urine albumin excretion was reduced 44% by valsartan versus 18% by amlodipine. It means that ARBs therapy has an antiproterinuric effect in a blood pressuredependent way in hypertensive 35 or normotensive patients with diabetic nephropathy. Other individual trials [17] [18] [19] [20] [21] 23, 24 included in this meta-analysis also have shown that the reduction of urinary protein excretion appears to be independent of the reduction of blood pressure in normotensive patients. However, this meta-analysis found that ARBs therapy was associated with significant decreases in SBP and DBP. Although the differences of blood pressure reduction were small between the ARBs group and the control group in this meta-analysis, it could not fully exclude a possible confounding effect of blood pressure reduction on the progression of urinary protein excretion in normotensive patients.
In our meta-analysis, there were no significant differences in the changes of serum creatinine and creatinine clearance between the two groups. No severe adverse events related to ARBs were reported. It is worth noting that in our study the dosages of ARBs were relatively low to usual recommended dose and the participants were all evaluated as chronic kidney disease stage 1-2 according to the criteria adopted by the National Kidney Foundation. 36 These data indicate that appropriate dosages of ARBs are safe and well tolerated in normotensive patients with proteinuria.
Limitations
The present study has the following limitations. First, the Zandbergen et al. trial 20 enrolled T2DM patients with microalbuminuria and a sitting blood pressure ≤ 150/90 mmHg, which is not consistent with the current definition of normotension. Because of the fact that the mean baseline blood pressures appeared to be 135.9/78.8 mmHg for the losartan group and 138.3/80.3 mmHg for the placebo group, the authors mentioned that the study sample could be considered normotensive. In addition, three trials 17,18,20 did not mention exclusion of patients previously treated with antihypertensive agents. Second, in order to evaluate the antiproteinuric effect of ARBs, we combined the different stages of nephropathy (early and overt nephropathy) and obtained the pooled estimate, which might induce clinical heterogeneity in this study. However, besides the overall estimate, subgroup analysis was also conducted to achieve respective effect estimates in different stages of nephropathic subjects. Third, urinary protein excretion was taken as a primary endpoint. The long-term effects of ARBs therapy on the cardiovascular and renal events are unable to be evaluated. Fourth, measurements of proteinuria were not consistent among the studies resulting in different units of measurement. For example, 24-hour urinary protein excretion (g/d), albumin excretion rate (μg/min) and urinary albumin-to-creatinine ratio (mg/g creatinine) were used for urinary protein excretion across trials. Finally, a moderate to high degree of statistical heterogeneity was observed. One potential explanation for the heterogeneity is different measurements. However, each trial showed a similar direction of antiproteinuric effects of ARBs therapy.
Conclusions
The data suggest that ARBs may have beneficial effects on preventing the progression of proteinuria in normotensive patients with renal disease. More studies, especially large multi-center RCTs, are still warranted to further clarify the effects of ARBs on cardiovascular and renal outcomes.
